Two founders from Carnegie Mellon and MIT just launched Onepot AI, aiming to make drug discovery much faster by automating the creation of difficult-to-make molecules. Their platform uses AI and robotic labs to synthesize compounds much faster and cheaper than traditional methods. The company says this could let pharma and biotech companies access a broader range of possible drug compounds, potentially opening up new avenues for treatments that were previously skipped due to synthesis challenges. They just came out of stealth with $13 million in funding from investors like Khosla Ventures and OpenAI’s Wojciech Zaremba, and are now expanding with a new lab in San Francisco.